TMX Newsfile News Releases (InvestorIdeas) [biotechnology]

Moss Genomics Inc. Provides Default Status Disclosure and Update on Continuous Disclosure Review

Tue, 25 Aug 2026 09:22:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - As a result of a review by the British Columbia Securities Commission (the "BCSC"), Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company") is issuing the following news release to clarify its disclosure.The Company advises that, on July 14, 2026, it was added to the BCSC's Issuers in Default list under Canadian Securities Administrators Notice 51-322 - Reporting Issuer Defaults. The default arises from comments...

BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy

Tue, 25 Aug 2026 08:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, is pleased to announce crucial updates reinforcing the clinical translation of its liquid biopsy technology platform for early non-small cell lung cancer (NSCLC) screening and risk stratification with the publication of two...

TempraMed Signs Definitive Five-Year Saudi Arabia Distribution Agreement for Private-Label VIVI Cap

Tue, 25 Aug 2026 07:00:00 -0400

HighlightsFive-year definitive agreement with approximately US$3.8 million in potential minimum purchase commitments, beginning with a firm 10,000-unit initial purchase order.Agreement covers a private-label version of VIVI Cap™ intended for retail commercialization through the physical pharmacy network of Nahdi Medical Company, Saudi Arabia's largest pharmacy chain.TempraMed believes the private-label structure can improve in-store commitment, pharmacist engagement and consumer promotion as the...

Theralase(R) Closes C$3.6 Million Brokered Financing

Mon, 24 Aug 2026 17:01:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering"), pursuant to which the Company issued 14,812,500...

NorthPalm Commits Entire Cybeats Position to a 12-Month Lock-Up; 60 Million Shares Representing Approximately 30% of Cybeats

Mon, 24 Aug 2026 09:39:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - NorthPalm Capital Corp. (CSE: NP) ("NorthPalm" or the "Company"), is pleased to announce that it has committed to a 12-month lock-up of its entire remaining position of 60,000,000 common shares of Cybeats Technologies Corp. (CSE: CYBT) ("Cybeats"), representing approximately 30% of Cybeats' outstanding shares.NorthPalm remains the largest institutional shareholder of Cybeats and is committed to maintaining a significant long-term ownership...

MustGrow Receives First Milestone Payment from Bayer AG

Fri, 21 Aug 2026 07:00:00 -0400

Bayer AG has paid MustGrow the first development milestone payment. The MustGrow / Bayer AG License and Collaboration Agreement, signed in December 2023, covers soil applications of MustGrow's mustard-based biocontrol technologies in Europe, Middle East and Africa.Saskatoon, Saskatchewan--(Newsfile Corp. - August 21, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) ("MustGrow") is pleased to announce that it has received the first milestone payment from Bayer AG (BAYN)...

Noveris Health Sciences Announces Proposed Private Placement of Convertible Debentures for up to $500,000

Thu, 20 Aug 2026 18:14:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") is pleased to announce its intention to complete a non-brokered private placement of convertible debentures of the Company (the "Debentures") in an aggregate principal amount of up to $500,000, issuable in increments of $1,000 principal amount, for aggregate gross proceeds of up to $500,000 (the "Offering"). The Offering is expected...

iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

Thu, 20 Aug 2026 16:05:00 -0400

Woburn, Massachusetts--(Newsfile Corp. - August 20, 2026) - iSpecimen, (NASDAQ: ISPC) a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order.The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline. Through its network of healthcare and research partners, iSpecimen coordinated...

Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA

Thu, 20 Aug 2026 09:44:00 -0400

Leading cognitive-disorders specialist, Dr. William Shankle, will discuss vascular cognitive impairment, vascular dementia and the proposed clinical trial of VesCell™ (ACP-01) today at 12:00 EST, at https://us06web.zoom.us/webinar/register/WN_nJ8ViLkRSeiU_NXMYJ-jbwCalgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce > 130 participants have enrolled to hear Dr. William R. Shankle, MS,...

Maxwell Biosciences' Spinout SHU.ai Announces Closing of $1M Financing Round

Thu, 20 Aug 2026 09:00:00 -0400

Austin, Texas--(Newsfile Corp. - August 20, 2026) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers®, December 5, 2025 incorporated its first spinout SHU.ai and June 27, 2026 announced the closing of SHU's $1 million Seed round. The round was oversubscribed and fully funded by private angel investors and led by Keiretsu Forum, "The World's Largest Angel Investor Network." The funds will support accelerating...